Is dexrazoxane recommended for cardioprotection in AYA patients with Hodgkin lymphoma who are receiving anthracyclines as part of their upfront therapy?

This is a good question that reflects the growing body of evidence in favor of dexrazoxane cardioprotection being safe and beneficial (Chow et al., PMID 26014292; Getz et al., PMID 32343641). For AYAs with Hodgkin lymphoma, doxorubicin remains a key component of therapy even for lower stage disease ...

While the initial concern of increased risk of a second malignancy has been diminished based on the analysis by Chow et. al (mentioned above), there is still some concern about higher risk for morbidity related to additive myelosuppression as the agent has topoisomerase properties.

The hematological...

I also agree, especially in HD - where if there is a relapse - chest radiation may be used. Better to protect the heart as much as possible from the start.